Tác động sống còn của xạ trị và hóa trị bổ trợ ở bệnh nhân bị ung thư nội mạc tử cung không phải nội mạc: phân tích PSM-IPTW dựa trên cơ sở dữ liệu SEER
Tóm tắt
Từ khóa
#ung thư nội mạc tử cung không phải nội mạc #xạ trị #hóa trị #PSM-IPTW #SEERTài liệu tham khảo
Yuce Sari S, Guler OC, Oymak E, Gultekin M, Yigit E, Kahvecioglu A, et al. Uterine papillary serous and clear cell carcinomas: comparison of characteristics and clinical outcomes. J Obstet Gynaecol Res. 2022;48:1876–87.
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, et al. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. J Natl Compr Canc Netw. 2021;19:888–95.
Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol. 2008;108:226–33.
Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012;2012:Cd003916.
Lancellotta V, De Felice F, Vicenzi L, Antonacci A, Cerboneschi V, Costantini S, et al. The role of vaginal brachytherapy in stage I endometrial serous cancer: a systematic review. J Contemp Brachytherapy. 2020;12:61–6.
Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, Casado SE. Adjuvant chemotherapy in endometrial cancer. Cancer Chemother Pharmacol. 2020;85:477–86.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:295–309.
Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, et al. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019;37:1810–8.
Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019;380:2317–26.
Squires BS, Quinn TJ, Nandalur SR, Jawad MS. Adjuvant radiotherapy improves overall survival when added to surgery and chemotherapy for uterine carcinosarcoma: a surveillance, epidemiology, and end results analysis. Int J Clin Oncol. 2021;26:2282–94.
Kane LT, Fang T, Galetta MS, Goyal DKC, Nicholson KJ, Kepler CK, et al. Propensity score matching: a statistical method. Clin Spine Surg. 2020;33:120–2.
Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656–64.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79.
Foreman J, Salim AT, Praveen A, Fonseka D, Ting DSW, Guang He M, et al. Association between digital smart device use and myopia: a systematic review and meta-analysis. Lancet Digit Health. 2021;3:e806–18.
Raffone A, Travaglino A, Raimondo D, Maletta M, De Vivo V, Visiello U, et al. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: a systematic review and meta-analysis of survival. Int J Gynaecol Obstet. 2022;158:520–7.
Altman AD, Ferguson SE, Atenafu EG, Köbel M, McAlpine JN, Panzarella T, et al. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. Gynecol Oncol. 2015;139:268–74.
Cham S, Huang Y, Tergas AI, Hou JY, Burke WM, Deutsch I, et al. Utility of radiation therapy for early-stage uterine papillary serous carcinoma. Gynecol Oncol. 2017;145:269–76.
Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375:816–23.
Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016;26:2–30.
Lin JF, Muñiz K, Sukumvanich P, Gehrig P, Beriwal S, Kelley JL, et al. Survival advantage associated with multimodal therapy in women with node-positive (stage-IIIC) uterine papillary serous carcinoma: a National Cancer Database study. BJOG. 2016;123:1846–52.
van Weelden WJ, Reijnen C, Eggink FA, Boll D, Ottevanger PB, van den Berg HA, et al. Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: a population-based study. Eur J Cancer. 2020;133:104–11.
Xiang M, English DP, Kidd EA. Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma. Gynecol Oncol. 2019;154:487–94.
Lee LJ, Demaria R, Berkowitz R, Matulonis U, Viswanathan AN. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. Gynecol Oncol. 2014;132:65–9.
Cuccu I, D’Oria O, Sgamba L, De Angelis E, GoliaD’Augè T, Turetta C, et al. Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives. Healthcare (Basel). 2023;15(11):571–82.
GoliaD’Augè T, Cuccu I, Santangelo G, Muzii L, Giannini A, Bogani G, et al. Novel Insights into Molecular Mechanisms of Endometrial Diseases. Biomolecules. 2023;9(13):499–501.